Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Trillium Therapeutics Inc. (TRIL)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/29/2021 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 11/22/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/22/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/19/2021 |
4
| Walker Paul Edward (Director) has filed a Form 4 on Trillium Therapeutics Inc.|
Txns:
| Disposed/sold 5,736,363 shares
@ $0
Disposed/sold 850,000 options to buy
@ $0.96, valued at
$816k
Disposed/sold 6,750,000 options to buy
@ $0
Disposed/sold 5,400,000 options to buy
@ $0.96, valued at
$5.2M
Disposed/sold 40,000 options to buy
@ $12.03, valued at
$481.2k
|
|
| 11/19/2021 |
4
| Pucci Paolo (Director) has filed a Form 4 on Trillium Therapeutics Inc.|
Txns:
| Disposed/sold 67,000 options to buy
@ $15.5, valued at
$1M
|
|
| 11/19/2021 |
4
| Myers Scott Dunseth (Director) has filed a Form 4 on Trillium Therapeutics Inc.|
Txns:
| Disposed/sold 67,000 options to buy
@ $9.51, valued at
$637.2k
|
|
| 11/19/2021 |
4
| Harrison Rosemary (See Remarks) has filed a Form 4 on Trillium Therapeutics Inc.|
Txns:
| Disposed/sold 75 shares
@ $0
Disposed/sold 180,000 options to buy
@ $14.11, valued at
$2.5M
|
|
| 11/19/2021 |
4
| BESHAR LUKE M (Director) has filed a Form 4 on Trillium Therapeutics Inc.|
Txns:
| Disposed/sold 40,000 options to buy
@ $12.03, valued at
$481.2k
Disposed/sold 6,666 options to buy
@ $0
Disposed/sold 547,656 restricted stock units
@ $0 |
|
| 11/19/2021 |
4
| Parsons James T. (CFO) has filed a Form 4 on Trillium Therapeutics Inc.|
Txns:
| Disposed/sold 180,000 options to buy
@ $12.03, valued at
$2.2M
Disposed/sold 94,792 options to buy
@ $0
Disposed/sold 59,896 options to buy
@ $0
Disposed/sold 5,761 options to buy
@ $0
Disposed/sold 36,204 options to buy
@ $0
Disposed/sold 24,390 options to buy
@ $0
Disposed/sold 30,171 options to buy
@ $0 |
|
| 11/19/2021 |
4
| Kamarck Michael E. (Director) has filed a Form 4 on Trillium Therapeutics Inc.|
Txns:
| Disposed/sold 67,000 options to buy
@ $14.77, valued at
$989.6k
|
|
| 11/19/2021 |
4
| Looker Benjamin (General Counsel) has filed a Form 4 on Trillium Therapeutics Inc.|
Txns:
| Disposed/sold 190,000 options to buy
@ $9.51, valued at
$1.8M
|
|
| 11/19/2021 |
4
| MACKEY CATHERINE J (Director) has filed a Form 4 on Trillium Therapeutics Inc.|
Txns:
| Disposed/sold 67,000 options to buy
@ $9.7, valued at
$649.9k
|
|
| 11/19/2021 |
4
| Bruns Ingmar (Chief Medical Officer) has filed a Form 4 on Trillium Therapeutics Inc.|
Txns:
| Disposed/sold 400,000 options to buy
@ $14.11, valued at
$5.6M
|
|
| 11/19/2021 |
4
| Petrova Penka (Chief Development Officer) has filed a Form 4 on Trillium Therapeutics Inc.|
Txns:
| Disposed/sold 38,808 options to buy
@ $0
Disposed/sold 4,574 options to buy
@ $0
Disposed/sold 49,480 options to buy
@ $0
Disposed/sold 83,960 options to buy
@ $0
Disposed/sold 140,000 options to buy
@ $12.03, valued at
$1.7M
|
|
| 11/19/2021 |
4
| Uger Robert (Chief Scientific Officer) has filed a Form 4 on Trillium Therapeutics Inc.|
Txns:
| Disposed/sold 102,083 options to buy
@ $0
Disposed/sold 58,333 options to buy
@ $0
Disposed/sold 5,260 options to buy
@ $0
Disposed/sold 23,473 options to buy
@ $0
Disposed/sold 29,073 options to buy
@ $0
Disposed/sold 250,000 options to buy
@ $12.03, valued at
$3M
|
|
| 11/19/2021 |
4
| TAYTON-MARTIN HELEN KATRINA (Director) has filed a Form 4 on Trillium Therapeutics Inc.|
Txns:
| Disposed/sold 40,000 options to buy
@ $12.03, valued at
$481.2k
Disposed/sold 498,294 restricted stock units
@ $0 |
|
| 11/19/2021 |
4
| Skvarka Jan (President and CEO) has filed a Form 4 on Trillium Therapeutics Inc.|
Txns:
| Disposed/sold 197,000 options to buy
@ $0
Disposed/sold 1,162,500 options to buy
@ $0
Disposed/sold 600,000 options to buy
@ $12.03, valued at
$7.2M
|
|
| 11/19/2021 |
SC 13D/A
| Growth Equity Opportunities V, LLC has filed a Schedule 13D for Trillium Therapeutics Inc. |
| 11/17/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 11/17/2021 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 11/17/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 11/17/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 11/17/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 11/17/2021 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 11/17/2021 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 11/16/2021 |
8-K
| Other Events Interactive Data |
| 11/12/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 10/29/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 10/27/2021 |
8-K
| Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits &... |
| 10/20/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/20/2021 |
8-K
| Other Events Interactive Data |
| 10/15/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/15/2021 |
8-K
| Other Events Interactive Data |
| 10/13/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
|
|
|